Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sertindole for schizophrenia.

R Lewis1, A-M Bagnall, M Leitner

  • 1Department of General Practice, North Wales Clinical School, Cardiff University, Gwenfro Unit 5, Wrexham Technology Park, Wrexham, UK, LL13 7YP. lewisr17@Cardiff.ac.uk

The Cochrane Database of Systematic Reviews
|July 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The brain under pressure: Exploring neurophysiological responses to cognitive stress.

Brain and cognition·2024
Same author

Goal-directed fluid therapy using uncalibrated pulse contour analysis and balanced crystalloid solutions during hip revision arthroplasty: a quality implementation project.

Journal of orthopaedic surgery and research·2023
Same author

Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC.

The European physical journal. C, Particles and fields·2022
Same author

Prospects for beyond the Standard Model physics searches at the Deep Underground Neutrino Experiment: DUNE Collaboration.

The European physical journal. C, Particles and fields·2021
Same author

Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults.

Beneficial microbes·2017
Same author

Brain abnormalities in high-risk violent offenders and their association with psychopathic traits and criminal recidivism.

Neuroscience·2015
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Sertindole (an atypical antipsychotic) is more effective than placebo for schizophrenia but may cause cardiac issues and weight gain. It shows fewer movement disorders than haloperidol but more cardiac anomalies and sexual dysfunction.

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Trial Analysis
  • Drug Safety and Efficacy

Background:

  • Sertindole, an atypical antipsychotic, was investigated for schizophrenia treatment due to a potentially lower incidence of extrapyramidal side effects compared to typical antipsychotics.
  • Concerns regarding cardiac arrhythmia and sudden cardiac death led to a voluntary suspension of sertindole in 1998, with subsequent re-evaluation and lifting of the suspension in 2001.
  • Post-marketing surveillance studies were initiated to gather further data on sertindole's safety and efficacy under normal usage conditions.

Purpose of the Study:

  • To evaluate the efficacy and safety of sertindole in comparison to placebo, typical antipsychotics, and other atypical antipsychotic drugs.
  • To assess sertindole's effects on schizophrenia and related psychotic disorders.

Main Methods:

Related Experiment Videos

  • A systematic literature search was conducted across multiple databases (MEDLINE, EMBASE, Cochrane Library, etc.) up to April 2003.
  • Inclusion criteria focused on randomized controlled trials comparing sertindole with placebo or other antipsychotic treatments for schizophrenia.
  • Data extraction and analysis included calculating risk ratios (RR), confidence intervals (CI), and weighted mean differences (WMD) for various efficacy and safety outcomes.

Main Results:

  • Sertindole (20mg/day) demonstrated greater efficacy than placebo in improving BPRS and CGI scores, with a marginally significant increase in 'very much improved' participants.
  • Compared to placebo, sertindole (20mg/day) was associated with significantly greater weight gain, and all doses showed a statistically significant difference in QT/QTc intervals.
  • Sertindole (24mg/day) showed better tolerability than haloperidol regarding study withdrawal and fewer movement disorders, but was associated with more cardiac anomalies, weight gain, rhinitis, and sexual dysfunction.

Conclusions:

  • Sertindole at 20mg/day is more antipsychotic than placebo, appearing similarly acceptable regarding movement disorders and somnolence, but with increased cardiac risks and weight gain.
  • Sertindole 24mg/day demonstrated improved tolerability over haloperidol, with reduced movement disorders and sedation, yet presented higher risks for cardiac issues, weight gain, rhinitis, and sexual dysfunction.
  • One study suggested sertindole 16mg/day as potentially the most optimal dose, highlighting a complex risk-benefit profile that varies with dosage.